Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL) | Synapse
March 3, 2026
Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL)
Key Points
Improved clinical outcomes are observed in younger patients with relapsed large B-cell lymphoma.
Treatment with lisocabtagene maraleucel shows significant efficacy in achieving durable responses.
Observational analysis of younger patients highlights the importance of tailored therapies for relapsed conditions.
Clinical outcomes from this intervention may support further exploration in broader populations.